Atea Pharmaceuticals, Inc.
AVIR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | -0.11 | 0.02 | -0.00 |
| FCF Yield | -48.00% | -33.58% | -30.70% | -11.75% |
| EV / EBITDA | -1.31 | -0.94 | -1.80 | -0.17 |
| Quality | ||||
| ROIC | -43.34% | -29.32% | -19.51% | 16.89% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 99.99% |
| Cash Conversion Ratio | 0.80 | 0.63 | 1.04 | -0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | – |
| Free Cash Flow Growth | -58.67% | 30.53% | -41.28% | -129.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.38 | 1.18 | 1.55 | -5.52 |
| Interest Coverage | 0.00 | 0.00 | -11.72 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,911.47 | -22.14 | -3,581.21 | -57,065.86 |